Indivior Pharmaceuticals, Inc. (INDV) Market Cap & Valuation Ratios
Indivior Pharmaceuticals, Inc. (INDV) has a market cap of $4.1B, a trailing P/E of 12.4 and a price-to-sales ratio of 3.0, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
INDVIndivior Pharmaceuticals, Inc.Follow INDV — free
—
Price chart with a free account
- Market cap
- 4.1B
- P/E TTM
- 12.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| INDV | 4.1 | 12.4 | 3.3 | 10.1 | -2.7% | +13% | 32% | 667% |
| ALKS | 7.3 | 114.8 | 4.9 | 45.6 | 3.0% | +11% | 7% | 3% |
| LNTH | 6.5 | 24.2 | 4.2 | 16.6 | 6.0% | +2% | 19% | 20% |
| AMRX | 6.5 | 41.6 | 2.9 | 14.0 | 1.3% | +9% | 15% | 17% |
| HIMS | 6.5 | — | 2.7 | — | 1.0% | +28% | -6% | -21% |
| KNSA | 6.0 | 78.3 | 6.5 | 53.5 | 3.1% | +59% | 12% | 18% |
| LQDA | 3.8 | 31.2 | 8.2 | 21.8 | 3.9% | +2234% | 37% | 180% |
| RGC | 3.8 | — | — | — | — | — | — | — |
| AMLX | 3.0 | — | — | — | -4.2% | — | — | -108% |
| SUPN | 2.4 | — | 2.6 | — | 0.8% | +25% | -16% | -15% |
| PBH | 2.3 | 13.4 | 3.8 | 13.0 | 10.4% | -1% | 26% | 6% |
| Median of these 10 | 36.4 | 4.0 | 19.2 | 3.0% | +18% | 13% | 6% |
P/E 12.4 vs. a peer median of 36.4; EV/Sales 3.3 vs. 4.0.
Growth vs. price
each dot a company · hover or tap for valuesHIMS and RGC and AMLX and SUPN have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Indivior Pharmaceuticals, Inc. — questions
- What is Indivior Pharmaceuticals, Inc.'s market cap?
- $4.1B.
- What is Indivior Pharmaceuticals, Inc.'s P/E ratio?
- 12.4 on trailing twelve-month earnings to 2026-06-30.
- What is Indivior Pharmaceuticals, Inc.'s price-to-sales ratio?
- 3.0.
Every figure on this page comes from Indivior Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.